Prednisolone Sodium Phosphate

What it’s used for

Orapred ODT (prednisolone sodium phosphate orally disintegrating tablet) is indicated in the treatment of the following diseases or conditions: Orapred ODT is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation ( 1 ) for the treatment of certain endocrine conditions ( 1 ) for palliation of certain neoplastic conditions ( 1 ) 1. 1 Allergic Conditions Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: Atopic dermatitis Drug hypersensitivity reactions Seasonal or perennial allergic rhinitis Serum sickness 1.

How to take it

Individualize dosing based on disease severity and patient response: Initial Dose: 10 mg to 60 mg of prednisolone (as 13. 4 mg to 80.

Important warnings

Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome and hyperglycemia: Monitor patients for these conditions with chronic use. Taper doses gradually for withdrawal after chronic use.

Common side effects

Common adverse reactions for corticosteroids include fluid retention, alteration in glucose tolerance, elevation in blood pressure, behavioral and mood changes, increased appetite and weight gain. Allergic Reactions: Anaphylactoid reaction, anaphylaxis, angioedema Cardiovascular: Bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, congestive heart failure, fat embolism, hypertension, hypertrophic cardiomyopathy in premature infants, myocardial rupture following recent myocardial infarction, pulmonary edema, syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis Dermatologic: Acne, allergic dermatitis, cutaneous and subcutaneous atrophy, dry scalp, edema, facial erythema, hyper or hypo-pigmentation, impaired wound healing, increased sweating, petechiae and ecchymoses, rash, sterile abscess, striae, suppressed reactions to skin tests, thin fragile skin, thinning scalp hair, urticaria Endocrine: Abnormal fat deposits, decreased carbohydrate tolerance, development of Cushingoid state, hirsutism, manifestations of latent diabetes mellitus and increased requirements for insulin or oral hypoglycemic agents in diabetics, menstrual irregularities, moon facies, secondary adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in trauma, surgery or illness), suppression of growth in children Fluid and Electrolyte Disturbances: Fluid retention, potassium loss, hypertension, hypokalemic alkalosis, sodium retention Gastrointestinal: Abdominal distention; elevation in serum liver enzyme levels (usually reversible upon discontinuation); hepatomegaly, hiccups, malaise, nausea, pancreatitis; peptic ulcer with possible perforation and hemorrhage; ulcerative esophagitis General: Increased appetite and weight gain Metabolic: Negative nitrogen balance due to protein catabolism Musculoskeletal: Aseptic necrosis of femoral and humeral heads; charcot-like arthropathy, loss of muscle mass; muscle weakness; osteoporosis; pathologic fracture of long bones; steroid myopathy; tendon rupture; vertebral compression fractures Neurological: Arachnoiditis, convulsions; depression, emotional instability, euphoria, headache; increased intracranial pressure with papilledema (pseudotumor cerebri) usually following discontinuation of treatment; insomnia, meningitis, mood swings, neuritis, neuropathy, paraparesis/paraplegia, paresthesia, personality changes, sensory disturbances, vertigo Ophthalmic: Exophthalmos; glaucoma; increased intraocular pressure; posterior subcapsular cataracts Reproductive: Alteration in motility and number of spermatozoa Postmarketing Experience Adverse reactions have been identified during post approval use of Orapred ODT.

Interactions

Aminoglutethimide: Aminoglutethimide may lead to loss of corticosteroid-induced adrenal suppression.

If pregnant or breastfeeding

5.

Forms & strengths

2.5 MG/ML / 100 MG/ML Ophthalmic Solution · 2.5 MG Delayed Release Oral Tablet · 5 MG Delayed Release Oral Tablet · 5 MG Disintegrating Oral Tablet · 0.03 MG/ML Ophthalmic Solution · 0.1 MG/ML Ophthalmic Solution · 0.3 MG/ML Ophthalmic Solution · 1 MG/ML Ophthalmic Solution · 3 MG/ML Ophthalmic Solution · 10 MG/ML Ophthalmic Suspension · 5 MG/ML Ophthalmic Solution · 1.25 MG/ML Ophthalmic Suspension · 5 MG Oral Tablet · 1 MG Oral Tablet · 25 MG Oral Tablet · 5 MG/ML Oral Solution · 5 MG Rectal Suppository · 25 MG/ML Injectable Suspension · 2 MG / 5 MG Oral Tablet · 3 MG/ML Oral Solution · 1 MG/ML Oral Solution · 10 MG/ML Ophthalmic Solution · 1.25 MG/ML Ophthalmic Solution · 50 MG Oral Tablet

Questions to ask your doctor or pharmacist

• Is this the right medicine for my condition, and how long should I take it?
• What side effects should I watch for, and which need urgent attention?
• Does this interact with my other medicines, supplements, or alcohol?
• What should I do if I miss a dose or take too much?